Home Science & Medicine Immunotherapy

Immunotherapy

Feature articles about current research in immunology that has significant impact or impact potential on thoracic oncology.

Takeaways from KEYNOTE-021 and IMpower 150 on Combination Chemotherapy and Checkpoint Inhibition in NSCLC

By Hossein Borghaei, MS, DO Posted: February 2018 The role of checkpoint inhibitors in the management of recurrent or metastatic NSCLC is now well established. For...

Immunotherapy Succeeds in Squamous NSCLC, Establishing a New Frontline Standard of Care

By Kara Nyberg, PhD Posted: August 2018 Treatment advances for metastatic squamous cell carcinoma have long lagged behind those for other NSCLC subtypes, forcing patients with...

PACIFIC Trial Leads to Durvalumab Approval in United States

The U.S. Food and Drug Administration approved durvalumab on February 16, 2018, for the treatment of patients with stage III NSCLC whose tumors are...

KEYNOTE-042: No Hard and Fast Rules for First-Line Pembrolizumab Regarding PD-L1–Positive Disease

By Kara Nyberg, PhD Posted: August 2018 The pace of research focused on new therapies for advanced NSCLC has progressed from a trot to a sprint...

PD-L1 IHC Blueprint Project” Presented at the AACR Annual Meeting 2016

By Erik J. MacLaren, PhD Immunotherapy with anti-PD-L1/PD-1 antibodies is rapidly changing the therapeutic landscape for patients with non-small cell lung cancer (NSCLC). However, selecting...

IMpower133: Finally Moving the Needle in SCLC

By Stephen V. Liu, MD Posted: March 1, 2019 The addition of atezolizumab to standard chemotherapy for extensive-stage SCLC achieved what, for decades, had been beyond...

The CRISPR-Cas9 Toolkit: Moving From Bench to Bedside

By Cynthia L. Kryder, MS Decades of immunology research have shown that it is possible to harness the power of the immune system to fight...

Explaining IMpower132: An Interview with Dr. Vassiliki A. Papadimitrakopoulou

Posted: December 2018 In the following interview, Vassiliki A. Papadimitrakopoulou, MD, Jay and Lori Eisenberg Distinguished Professor of Medicine and section chief of Thoracic Medical...

Management of Immunotherapy Toxicity in NSCLC

By Beth Eaby-Sandy, MSN, CRNP Posted: February 2018 When I started in thoracic medical oncology 15 years ago, we just had chemotherapy, and patient education was...

Exploring the Potential of Immuno-oncology Combination Therapy

By Cynthia L. Kryder, MS, CCC-Sp Posted: October 2017 Editor Note: The article is part of a newly launched ongoing series about immunooncology (IO) combination therapy,...

Meeting News